

PAPER • OPEN ACCESS

Effect of Active Compound of Pasak Bumi Root (*Euricoma longifolia*, Jack) as an inhibitor of CDK2 methylation: *In Silico* Study

To cite this article: E Y Rahman *et al* 2019 *J. Phys.: Conf. Ser.* **1374** 012004

View the [article online](#) for updates and enhancements.



IOP | ebooks™

Bringing you innovative digital publishing with leading voices to create your essential collection of books in STEM research.

Start exploring the collection - download the first chapter of every title for free.

Effect of Active Compound of Pasak Bumi Root (*Euricoma longifolia*, Jack) as an inhibitor of CDK2 methylation: *In Silico* Study

E Y Rahman^{1,2*}, M Ali³, B B Purnomo⁴, N Kania⁵, D H Utomo⁶ and P W Nurikhwan⁷

¹Doctoral Program of Medical Science, Faculty of Medicine, University of Brawijaya Malang, Indonesia

²Department of Surgery, Urology Division, Faculty of Medicine, University of Lambung Mangkurat Banjarmasin, Indonesia

³Department of Pharmacology, Faculty of Medicine, University of Brawijaya Malang, Indonesia

⁴Department of Urology, Faculty of Medicine, University of Brawijaya Malang, Indonesia

⁵Department of Anatomical Pathology, Urology Division, Faculty of Medicine, University of Lambung Mangkurat Banjarmasin, Indonesia

⁶Department of Biology, Faculty of Mathematics & Natural Science, University of Brawijaya Malang, Indonesia

⁷Department of Medical Education, Faculty of Medicine, University of Lambung Mangkurat Banjarmasin, Indonesia

*Corresponding author's email: eyurologi05@gmail.com

Abstract. Active compound of Pasak Bumi's root, a native plant of Indonesia, is used as antitumor by triggering cell apoptosis and reactivating the silence tumor suppressor gene caused by hypermethylation, inhibiting cancer cell proliferation. The aim of this study is to know the role of quassinoid from Pasak Bumi's root (*Eurycoma longifolia* Jack) as an inhibitor of CDK2 methylation *in silico*. This is a descriptive study. CDK2 samples are obtained from Protein Data Bank (RSCB.org) with ID3SWR, samples of natural quassinoid are obtained from PUBCHEM NCBI and controlled by Sunitinib (®Sutent). Autodock Vina program PyRx 0.8 is used to analyze Molecular Docking. The process of analyzing molecular interactions is carried out using the LigandScout V.2.0 program. Visualization process are carried out using LigandScout V.2.0 program. The affinity of quassinoid and sutinab to CDK are -6.1 and -9.4, respectively. The more negative the binding affinity value, the better the ability of the compound (ligand) to bind to the receptor (macromolecules). From this case, Sutinab has better value compared to quassinoid. Target protein analysis using HITPICK shows quassinoid's target predictor is JUN protein. Protein interaction analysis are obtained, and the compound is using stitch. JUN protein and Sunitib could bind with CDK2. The conclusion of this study is Sutinib has greater affinity compared to quassinoid.

Keywords : herbal compound, quassinoid, Pasak bumi root, antiproliferation, CDK2, prostate cancer cell line



1. Introduction

In United States 2014, around 233,000 new cases and around 29,480 deaths from prostate cancer [1]. The etiology of prostate cancer is still controversial. Genetic and epigenetic play a role in the process of prostate cancer carcinogenesis. Genes that experience mutations in prostate cancer are the p53, p16 (CDKN2A), PTEN, bcl-2, race, p27 (CDKN1B), and caspase genes [2,3]. The p27 tumor suppressor gene (p27 gene) is a gene that has hypermethylation in prostate cancer. The p27 gene is proven to be activated by hypermethylation promoter in prostate cancer [2], whereas PTEN inhibits AKT phosphorylation, which is required for activation and targets many effectors [4]. PTEN may loss (events that are common in the treatment of poorly differentiated and resistant prostate cancer) and cause activation of the P13K / AKT pathway and subsequent apoptotic resistance [5]. Restoration of PTEN activity in prostate cancer cells PTEN deficiency has been shown to increase sensitivity and encouraging apoptosis [6].

Based on above, prostate cancer epigenetic changes occur due to hypermethylation of tumor suppressor genes p27 and PTEN. The reversible nature of epigenetic changes in cancer results in the possibility of epigenetic therapy as an alternative treatment. The aim of epigenetic therapy is to reverse the causes of epigenetic changes that occur in cancer so that the normal epigenome condition returns. DNA methylation inhibitor compounds are the first epigenetic drugs proposed as drugs for cancer therapy.

Herbal therapy can be an alternative. Several types of bioactive components derived from herbs that have the ability to inhibit the work of the DNA methyltransferase (DNMT) enzyme can affect DNA methylation processes and have barriers to cancer activation through reactivation of tumor suppressor genes that experience silencing [6-14]. Flavonoids can reactivate suppressor tumor genes that have undergone silencing due to hypermethylation [15,16].

Eurycoma longifolia Jack or the Pasak Bumi plant can be an alternative herbal therapy choice. Pasak bumi is a tropical plant belonging to the Simaroubaceae family that is distributed in Southeast Asian countries, native plants in South Kalimantan [17]. *Eurycoma longifolia* has biological active ingredients found in the roots. Pasak Bumi (*Eurycoma longifolia* Jack) is one of the plants that has been used as a drug for detoxification, free radical antioxidants, and anticancer [18,19]. The compounds contained in *E. longifolia* are quassinoid [18,20,21] and 9-methoxycanthin-6-on alkaloids [22,23] and canthinone alkaloids [24]. Quassinoid is a triterfenoid compound that has a flavonoid-like structure so that the Pasak Bumi root quassinoid compound has the potential as a demethylating agent.

Cheah and Azihmahtol's [25] study showed that methanol extract of *E. longifolia* can induce apoptosis in MCF-7 breast cancer cell line through a decrease in Bcl-2 expression [25]. 9-methoxycanthin-6-on compounds from methanol extract and chloroform *E. longifolia* have a cytostatic effect on ovarian cancer cells (CaOv3), epidermoid carcinoma (KB), breast cancer (MCF-7) and rhabdosarcoma (RB) [22]. Conscience research in vitro and in vivo using ethanol extract on breast cancer cells produced inhibitory activity of COX-2 expression, decreased BCL-2 expression, increased Caspase 3, increased expression of p53, increased expression of p21, increased expression of GADD45 and decreased Ras [26]. This shows that the *E. longifolia* Jack has the potential as a new active drug for cancer suppression.

Based on the thinking above the active compound of the Pasak Bumi root (*E. Longifolia* Jack) has cytotoxic effects on various cancers such as colon cancer, breast cancer, lung cancer, skin cancer (melanoma), ovarian cancer, and others, it is necessary to know whether it is also cytotoxic in prostate cancer that is independent androgen (hormonal resistant therapy). According to author's knowledge, study on the potential of the Pasak Bumi's roots is still few especially study for hypermethylation, and inhibiting cancer cell proliferation in Prostate Cancer (PC-3 CDK2). This later became the background of the authors to conduct research on the potential of Pasak Bumi's roots in inhibiting proliferation and increasing apoptosis in PC-3 Prostate Adenocarcinoma cells. The aim of this study is to know the role of quassinoid from Pasak Bumi's root (*Eurycoma longifolia* Jack) as an inhibitor of CDK2 methylation in Prostate Cancer (PC-3) *in silico*.

2. Materials and Methods

2.1. Design

This study using descriptive method to identify the Quassinoid compound found in the roots of Pasak Bumi (*E. longifolia* Jack) and identify its potential in antiproliferation *in silico study*,. For positive control ligand, this study used Oral, small-molecule Sunitinib (marketed as Sutent by Pfizer), is a multi-targeted receptor tyrosine kinase (RTK) inhibitor that is approved for treatment of renal cell carcinoma (RCC) and imatinib-resistant stromal gastrointestinal tumor (GIST) on January 26, 2006. Sunitinib was approved as the first line for cancer drug in two different indications.

2.2. Procedure

2.2.1. *The Interaction between Pasak Bumi's Quassinoid and PTEN(CDK2)*. CDK2 samples are obtained from Protein Data Bank (RSCB.org) with ID3SWR. This model is human CDK2 protein which has been linked to an inhibitor, while a sample of quassinoid natural ingredients is obtained from PUBCHEM NCBI and controlled by Sunitinib (@Sutent). The potential of each compound in inhibiting CDK2 was analyzed by looking at the affinity of the compound in binding to the active side of CDK2. The Molecular Docking analysis process is done using Autodock Vina on the PyRx 0.8 program. The Docking process is carried out on the active side of the CDK2.

3. Result and Discussion

The aim of this study is to know the role of quassinoid from Pasak Bumi's root (*Eurycoma longifolia* Jack) as an inhibitor of CDK2 methylation *in silico*. This study found that the quassinoid has an affinity as inhibitor of CDK2. In this study, the composition of *in silico* study are ie Quassinoid Analog as ligand, CDK2 (3TI1) as macromolecule, and SUNITINIB ($C_{22}H_{27}FN_4O_2$) as Positive control ligand. The affinity of quassinoid and Sunitinib to CDK are -6.1 and -9.4, respectively (Table 1). Ligand's ability to bind with receptor (macromolecule) is shown by its negativity towards binding affinity, the more negative the binding affinity value, the better the ability of the compound (ligand) to bind to the receptor (macromolecules). In this case, Sunitinib has better value compared to quassinoid means Sunitinib has better ability to bind than quassinoid

Table 1. Result.

	Quassinoid (Binding affinity)	Sunitinib (Binding affinity)
CDK2	-6.1	-9.4

To analyse target protein of quassinoid after binding, HITPICK was used. As seen in figure 1, Protein target analysis using HITPICK shows that the target prediction of the quassinoid is JUN protein. Then the interaction analysis between protein and compounds is done using stitch. JUN proteins and Sunitinib could bind with CDK2. CDK2 Serine / threonine-protein kinase is involved in cell cycle control, meiosis, and triggers duplication of centrosomes and DNA. CDK2 has an important role in regulating a good balance between cellular proliferation, cell death, and DNA repairing in human embryonic stem cells (hESCs). By binding the quassinoid to CDK, the cellular proliferation and cell death may be balanced. Figure 2 explained this mechanism, If P21 / P27 is not phosphorylated, the CDK2 activity increases, increasing tumorigenesis and abnormal cell cycle regulation. P27 is a CDK inhibitor. Drugs that work in inhibiting CDK2 have a function to arrest the cell cycle.




Figure 1. Action type and effect toward CDK2. Green line: Sunitinib. Pink line: Quassinoid.




Figure 2. CDK2 Regulation in tumorigenesis.

The limitation of this study is there is no other marker or protein whom assessed. Future study with more protein involvement is needed.

4. Conclusion

The role of quassinoid of Pasak Bumi's root (*Eurycoma longifolia* Jack) is an inhibitor of CDK2 methylation as in silico study with a lesser affinity compared to Sunitinib.

References

- [1] Isaacs W and Kainu T 2001 Oncogenes and tumor suppressor genes in prostate cancer *Epidemiol. Rev.* **1** 36-41
- [2] Dharmayanti N L P 2003 Kajian Biologi Molekuler : gen suppressor tumor (p53) sebagai target gen dalam pengobatan kanker *J. Wartazoa* **13** (30) 54-60
- [3] Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, Thomas G V, Li G, Roy-Burman P, Nelson P S, Liu X and Wu H 2003 Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer *Cancer Cell* **4** (3) 209–221
- [4] Davies M A, Koul D, Dhese H, Berman R, McDonnell T J, McConkey D, Yung W K and Steck P A 1999 Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN *Cancer Res.* **59** (11) 2551–2556
- [5] Yuan X J and Whang Y E 2002 PTEN sensitizes prostate cancer cells to death receptor-mediated and drug-induced apoptosis through a FADD-dependent pathway *Oncogene* **21** (2) 319–327
- [6] Yoo C B and Jones P A 2006 Epigenetic therapy of cancer: past, present and future *Nature review* **5** 37-50
- [7] Esteller M 2008 Molecular origins of cancer: Epigenetic in cancer *The New England Journal of Medicine* **358** (11) 1148-1159
- [8] Li Y and Tollefsbol T O 2010 Impact on DNA methylation in cancer prevention and therapy by bioactive dietary component *Curr. Med. Chem.* **17** (20) 2141-2151
- [9] Meeran S M, Ahmed A and Tollefsbol T O 2010 Epigenetic targets of bioactive dietary component for cancer prevention and therapy *Clin. Epigenetic* **1** 101-116
- [10] Sharma S, Kelly T K and Jones P A 2010 Epigenetic in cancer *Carcinogenesis* **31** (1) 27-36
- [11] Azad N, Zahnow C A, Rudin C M and Baylin S B 2013 The future of epigenetic therapy in solid tumours-lesson from the past *Nat. Rev. Clin. Oncol.* **10** 1-11
- [12] Lee W J, Shim J Y and Zhu B T 2005 Mechanism for the inhibition of DNA methyltransferases by tea catechins and bioflavonoids *Mol. Pharmmacol.* **68** 108-1030

- [13] Fang M, Chen D and Yang C S 2007 Dietary polyphenol may affect DNA methylation *The Journal of Nutrition* **137** 223-228
- [14] Rege Y D and Rangnekar V M 2004 Molecular therapy intervention prospects in prostate cancer *Curr. Pharm. Des.* **10** 523-30
- [15] Zhang C, Gao C, Xu Y and Zhang Z 2004 CtBP2 could promote prostate cancer cell proliferation through c-Myc signaling *Gene* **546** 73-79
- [16] Rahman A S, Sim Yap M M, Md. Shakaff A Y, Ahmad M N, Dahari Z, Ismail Z and Hitam M S 2004 A microcontrollerbased taste sensing system for the verification of *Eurycoma longifolia* *Sens. Actuators B* **101** 191-198
- [17] Ang H H, Ngai T H and Tan T H 2003 Effects of *Eurycoma longifolia* Jack on sexual qualities in middle aged male rats *Phytomed.* **10** 590-593
- [18] Schmitt B, Bennett C L, Seidenfeld J, Samson D and Wilt T 2000 Role of Maximal androgen blockade for advanced prostate cancer *Cochrane Database Syst. Rev.* **2** D001526
- [19] Bouillet P and Strasser A 2002 BH3-only proteins – evolutionarily conserved proapoptotic Bcl-2 family members essential for initiating programmed cell death *Journal of Cell Science* **115** 1567-1574
- [20] Nuryamin A 2000 *Studi Potensi Tumbuhan Obat Akar Kuning (Arcangelisia flava L. Merr), Pasak Bumi (Eurycoma longifolia Jack), Seluang belum (Luvunga eleutheranda Dalz) dan Gin Kalimantan (Psychotria valetonii I lochr)* Skripsi Jurusan Konservasi Sumberdaya Hutan Fakultas Kehutanan IPB
- [21] Nurkhasanah M and Azimahtol H L P 2008 Eurycomanone Induces Apoptosis through the Up-Regulation of p53 in Human Cervical Carcinoma Cells *Journal of cancer molecules* **4** 109-115
- [22] Tannock I F, de Wit R, Berry W R, Horti J, Pluzanska A, Chi K N, Oudard S, Théodore C, James N D, Turesson I, Rosenthal M A and Eisenberger M A 2004 Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer *New Engl. J. Med.* **351** (15) 1502-12
- [23] Chan K L, Choo C Y, Abdullah N R and Ismail Z 2004 Antiplasmodial studies of *Eurycoma longifolia* Jack using the lactate dehydrogenase assay of *Plasmodium falciparum* *J. Ethnopharmacol.* **92** 223-227
- [24] Chuen C S and Pihie A H L 2004 Eurycomanone exert antiproliferative activity via apoptosis upon MCF-7 cells *Proc. Sym. Biol. Kebangsaan Malaysia ke-7* 73-77
- [25] Nurani L H and Mubarika S 2011 *Mekanisme Molekuler Kemopreventif dan Antikanker Senyawa Aktif Akar Pasak Bumi (Eurycoma longifolia Jack) Kajian In vitro pada sel T47D dan In vivo pada Kanker Payudara pada Tikus SD yang diinduksi DMBA* Universitas Gajah Mada
- [26] Chan K L, Choo C Y and Abdullah N R 2005 Semisynthetic 12-O-Acyl- and 1,15-Di-O-acyleurycomanones from *Eurycoma longifolia* as potential antimalarial *Planta Med.* **71** 967-69